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Introduction and Aim: Hemorrhagic transformation (HT) frequently occurs after acute
ischemic stroke and negatively influences the functional outcome. Usually, HT is classified
by its radiological appearance. Discriminating between the subtypes can be complicated,
and interobserver variation is considerable. Therefore, we aim to quantify rather than
classify hemorrhage volumes and determine the association of hemorrhage volume with
functional outcome in comparison with the European Cooperative Acute Stroke Study
II classification.
Patients and Methods: We included patients from the MR CLEAN trial with follow-up
imaging. Hemorrhage volume was estimated by manual delineation of the lesion, and HT
was classified according to the European Cooperative Acute Stroke Study II classification
[petechial hemorrhagic infarction types 1 (HI1) and 2 (HI2) and parenchymal hematoma
types 1 (PH1) and 2 (PH2)] on follow-up CT 24 h to 2 weeks after treatment. We assessed
functional outcome using the modified Rankin Scale 90 days after stroke onset. Ordinal
logistic regression with and without adjustment for potential confounders was used to
describe the association of hemorrhage volume with functional outcome. We created
regression models including and excluding total lesion volume as a confounder.
Results: We included 478 patients. Of these patients, 222 had HT. Median hemorrhage
volume was 3.37ml (0.80–12.6) and per HT subgroup; HI1: 0.2 (0.0–1.7), HI2: 3.2
(1.7–6.1), PH1: 6.3 (4.2–13), and PH2: 47 (19–101). Hemorrhage volume was associated
with functional outcome [adjusted common odds ratio (acOR): 0.83, 95% CI: 0.73–0.95]
but not anymore after adjustment for total lesion volume (acOR: 0.99, 95%CI: 0.86–1.15,
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per 10ml). Hemorrhage volume in patients with PH2 was significantly associated with
functional outcome after adjusting total lesion volume (acOR: 0.70, 95% CI: 0.50–0.98).
Conclusion: HT volume is associated with functional outcomes in patients with acute
ischemic stroke but not independent of total lesion volume. The extent of a PH2 was
associated with outcome, suggesting that measuring hemorrhage volume only provides
an additional benefit in the prediction of the outcome when a PH2 is present.
Keywords: ischemic stroke (IS), hemorrhagic transformation (HT), intracranial hemorrhage (ICH), endovascular
therapy (EVT), hemorrhage volume, thrombolysis
INTRODUCTION
Hemorrhagic transformation (HT) commonly occurs as
a natural progression or as a complication of reperfusion
therapy for acute ischemic stroke (1, 2). Large, but also
small HT subtypes were found to be associated with poor
functional outcome (3). Incidence varies and differences in
definition of HT between studies complicate comparisons
between studies. Usually, HT is classified according to the
European Cooperative Acute Stroke Study II (ECASS II)
classification based on radiological appearance (4). This
classification divides HT in four groups: hemorrhagic infarction
type 1 (HI1), which is defined as small petechiae along the
margins of the infarct; hemorrhagic infarction type 2 (HI2),
defined as confluent petechiae within the infarcted area but
no space-occupying effect; parenchymal hematoma type 1
(PH1) as blood clots in 30% or less of the infarcted area
with some slight space-occupying effect; and parenchymal
hematoma type 2 (PH2) as blood clots in more than
30% of the infarcted area with substantial space-occupying
effect (4).
The ECASS classification only takes hemorrhage volume
relative to the infarct volume into account when a PH is
present, and therefore, small hemorrhages could be classified
as PH2 when the infarct is small. The opposite is true
when large hematomas develop within massive infarcts. These
hematomas are not classified as PH2 when their relative size is
<30% of the infarct while their objective size could be more
than 40ml. These hemorrhages might lead to symptomatic
intracranial hemorrhage (sICH). However, according to the
Heidelberg Bleeding classification, ICH other than PH2 might be
symptomatic, but it is advised not to classify those hemorrhages
as sICH (5).
Further, an agreement between observers for HT is only fair,
as discriminating between HT subtypes can be challenging (6, 7).
This limited agreement might contribute to a variation in the
reported incidence of HT between studies.
As an alternative to the current rather crude classification
of HT, we aim to quantify the hemorrhage volume of
patients with HT and to assess its prognostic value by
determining the association of hemorrhage volume with
functional outcome in comparison with the ECASS II
classification. Additionally, we determine whether hemorrhage
volumes smaller than 30% of lesion volume might have
been symptomatic.
METHODS
We included all patients with follow-up imaging from the MR
CLEAN trial (8). The MR CLEAN trial was a multicenter
randomized controlled trial that assessed the safety and efficacy
of endovascular therapy compared with usual care after acute
ischemic stroke due to large vessel occlusion. The MR CLEAN
study protocol has been described previously (9).
We assessed potential HT on follow-up CT scans that were
acquired ∼5 days after inclusion. When these scans were not
available, 24-h follow-up CT scans were examined. Hemorrhage
volume was measured by a trained observer (KRK) by manually
delineating the hemorrhages using ITK-SNAP (version 3.4.0).
Hemorrhage volume consists of all hemorrhage present on the
CT scan, including concomitant intraventricular hemorrhage
and subarachnoid hemorrhage. HT was classified according to
the ECASS II classification (4). In the MR CLEAN trial, sICH was
classified as neurologic deterioration with an increase of more
than four points on the National Institute of Health Stroke Scale
and hemorrhage visible on imaging (8).
The functional outcome was assessed at ∼90 days after stroke
onset and attributed with a score according to the modified
Rankin Scale (mRS). The mRS ranges from 0 to 6, where 0
indicates no symptoms and 6 indicates death.
Statistical Analysis
Mean and SD are used to summarize normally distributed
variables; for non-normal distributed variables, the median
and interquartile range are used. We compared hemorrhage
volumes between all HT subtypes using a Kruskal–Wallis test.
The association of hemorrhage volume with functional outcome
was assessed using ordinal logistic regression analysis using
the full mRS scale as the outcome measure. The association
of hemorrhage volume with functional outcome was estimated
as a common odds ratio (cOR) per 10-ml increase, expressing
the relative risk of a shift in the direction of good outcomes
for every 10ml of hemorrhage. A cOR < 1 indicates a shift
toward worse outcomes on the mRS. Three models were made;
in the first model, we assessed the association of hemorrhage
volume with functional outcome. In the second model, we
assessed the association of hemorrhage volume and all HT
subgroups with functional outcome, and the third model
described the association of hemorrhage volume and sICH with
functional outcome. We adjusted every model for potential
confounders: diabetesmellitus, systolic blood pressure (measured
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FIGURE 1 | Quantification of Hemorrhagic Transformation per subtype.
on admission), intravenous thrombolysis, endovascular therapy,
time from onset to randomization, history of ischemic stroke,
age, atrial fibrillation, and baseline National Institutes of Health
Stroke Scale. We conducted an additional subgroup analysis to
assess the association of hemorrhage volume with functional
outcome per HT subgroup.
Follow-up lesion volume included both infarct and
hemorrhage volume and was estimated using a validated
automated measurement (10). In some patients with a large
PH, the lesion volume is equal to the hemorrhage volume,
and the actual infarct is masked by hemorrhage. Adjusting for
follow-up lesion volume might result in an underestimation
of the impact of hemorrhage volume. However, HT is more
likely to occur within large infarcts, and not adjusting for lesion
volume could overestimate the impact of HT. Therefore, we
conducted analyses with additional adjustment for follow-up
lesion volume. We conducted the statistical analysis using R {R
Core Team [V.4.0.0 (2020)]; R: A language and environment for
statistical computing, R Foundation for Statistical Computing,
Vienna, Austria; used packages rms (11), ggplot2 (12), and
tableone (13)}.
RESULTS
Of all the patients with follow-up imaging (n = 478), 222 had
HT. Of these 222 patients with HT, we measured hemorrhage
volumes of 219 patients (Figure 1). Hemorrhage volumes of
three patients could not be measured due to insufficient
image quality.
Hemorrhage volumes differed between HT subgroups (p <
0.001). Patients with PH2 had the largest hemorrhage volumes
[46.8 (interquartile range: 19–101) ml] (Table 1).
Hemorrhage volume was significantly associated with worse
functional outcomes in the unadjusted and adjusted analyses
[cOR 0.75, 95% confidence interval (CI) 0.67 to 0.83 and acOR
0.77, 95% CI: 0.69 to 0.87 per 10ml] (Figure 2). After additional
adjustment for follow-up lesion volume, the association was
weaker (acOR 0.90, 95% CI 0.80 to 1.02) (Table 2, Model 1).
In model 2, the analysis that included hemorrhage volume
and all HT subgroups, hemorrhage volume and all HT subgroups
except PH2 with no HT as reference level were significantly
and independently associated with functional outcome in the
adjusted and unadjusted analyses. After additional adjustment for
follow-up lesion volume, only HI2 and PH2 were associated with
functional outcome (acOR 0.57, 95% CI 0.34 to 0.95 and acOR
0.36, 95% CI 0.14 to 0.97, respectively).
Subgroup Analysis
Hemorrhage volume in patients with PH2 was significantly
associated with functional outcome in the adjusted analysis,
including follow-up lesion volume (acOR 0.70, 95% CI 0.50 to
0.98). This association was not observed in the other HT subtypes
(Figure 3).
Symptomatic Intracranial Hemorrhage
Thirty-five patients with HT were classified as sICH (example
in Figure 4). The median hemorrhage volume of patients
with sICH was 53 (24–106) ml. Of those patients with
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Hemorrhage volume, ml—median (IQR) 0 (0–0) 0.17 (0–1.7) 3.2 (1.7–6.1) 6.3 (4.2–12.9) 46.8 (18.7–100.7)
EVT—no. (%) 111 (43.4) 28 (36.8) 35 (49.3) 21 (58.3) 17 (43.6)
Treatment with IV alteplase—no. (%) 228 (89.1) 66 (86.8) 65 (91.5) 33 (91.7) 36 (92.3)
Age—mean (SD) 64 (14.3) 65 (12.6) 66 (12.9) 64 (14.8) 68 (14.1)
Baseline NIHSS—mean (SD) 17 (5.7) 19 (6.1) 18 (4.4) 18 (4.3) 19 (4.8)
History of ischemic stroke—no. (%) 26 (10.2) 7 (9.2) 8 (11.3) 1 (2.8) 9 (23.1)
Atrial fibrillation—no. (%) 58 (22.7) 17 (22.4) 25 (35.2) 15 (41.7) 14 (35.9)
Diabetes mellitus—no. (%) 27 (10.5) 13 (17.1) 9 (12.7) 5 (13.9) 7 (17.9)
Systolic blood pressure—mean (SD) 143 (22.4) 144 (26) 142 (27.5) 153 (23.6) 160 (31.4)
Time from stroke onset to randomization per minute—median (IQR) 193 (147–254) 217 (148–258) 207 (158–281) 213 (165–278) 223 (181–265)
Follow-up lesion volume—median (IQR) 47 (18–118) 132 (58–207) 120 (78–243) 172 (97–274) 165 (93–323)
EVT, endovascular treatment; HT, hemorrhagic transformation; HI, hemorrhagic infarction; PH, parenchymal hematoma; NIHSS, National Institute Of Health Stroke Scale; IQR,
interquartile range.
FIGURE 2 | Hemorrhage volume and functional outcome per HT subgroup.
sICH, 14 had hemorrhages <30% of lesion volume. Some
of these hemorrhages likely caused symptoms, whereas
in some sICH, not only hemorrhage would have caused
symptoms but also infarct growth probably contributed to the
neurological deterioration.
In model 3, hemorrhage volume and sICH were both
significantly associated with functional outcome (cOR
0.83, 95% CI 0.73 to 0.95) and the unadjusted analysis
(cOR 0.31, 95% CI 0.12 to 0.78). In the adjusted analyses,
sICH was not significantly associated with functional
outcome (acOR 0.45, 95% CI 0.17 to 1.17) (Table 2). After
additional adjustment for follow-up lesion volume, the
association of hemorrhagic volume with functional outcome
was attenuated.
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TABLE 2 | Adjusted and unadjusted OR’s of the association of hemorrhage volume in ml with functional outcome.
Model Unadjusted OR and 95% CI Adjusted OR and 95% CI Adjusted OR and 95% CI
(with FLV)
1 Hemorrhage volume, per 10ml 0.75 (0.67 to 0.83) 0.77 (0.69 to 0.87) 0.90 (0.80 to 1.02)
2 Hemorrhage volume, per 10ml 0.79 (0.69 to 0.90) 0.83 (0.73 to 0.95) 0.99 (0.86 to 1.15)
HI1 0.42 (0.27 to 0.65) 0.56 (0.36 to 0.89) 0.68 (0.42 to 1.06)
HI2 0.40 (0.24 to 0.64) 0.44 (0.27 to 0.71) 0.58 (0.34 to 0.96)
PH1 0.46 (0.25 to 0.85) 0.41 (0.22 to 0.78) 0.72 (0.37 to 1.41)
PH2 0.55 (0.23 to 1.31) 0.50 (0.20 to 1.24) 0.37 (0.14 to 0.98)
3 Hemorrhage volume, per 10ml 0.83 (0.73 to 0.95) 0.83 (0.73 to 0.95) 0.94 (0.80 to 1.09)
sICH 0.31 (0.12 to 0.78) 0.45 (0.17 to 1.17) 0.69 (0.23 to 2.07)
The association of hemorrhage volume in milliliters with the full scale mRS score.
This table lists the association of hemorrhage volume with the full scale mRS score.
Adjusted for HT classification, atrial fibrillation, baseline NIHSS, intravenous thrombolysis, diabetes mellitus, time from stroke onset to randomization, age, endovascular therapy, previous
stroke, systolic blood pressure (measured on admission). An additional analysis was conducted with follow-up lesion volume included in the adjusted analysis.
In models 2 and 3, no HT and no sICH were used as reference level when assessing the association of HT subgroups and sICH with functional outcome.
FLV, Follow-up lesion volume; HT, hemorrhagic transformation; HI, hemorrhagic infarction; PH, parenchymal hematoma; sICH, symptomatic intracranial hemorrhage; mRS, modified
Rankin Scale.
FIGURE 3 | Adjusted OR and 95% CI of the subgroup analysis of hemorrhage volume and its association with functional outcome per HT subgroup.
DISCUSSION
We have shown that hemorrhage volume and the ECASS
classification are associated with functional outcomes
independently of each other. In the adjusted analysis,
hemorrhage volume was associated with functional outcome, and
PH2 was not associated with functional outcome. This was also
seen in the analysis with sICH. However, in the adjusted analysis
that included follow-up lesion volume, hemorrhage volume
was not associated with functional outcome. In the subgroup
analysis, only hemorrhage volume of PH2 was associated with
functional outcome.
Previous studies suggested that hemorrhage volume could be
more appropriate than a radiological classification, as it gives a
more objective description when assessing HT (14, 15). These
studies had a relatively small sample size compared with the
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FIGURE 4 | Examples of possible and unlikely sICH with hemorrhage volume < 30% of lesion volume. (A) Hemorrhage volume: 65ml, lesion volume: 279ml,
hemorrhage (%): 24%. (B) Hemorrhage volume: 61ml, lesion volume: 275ml, hemorrhage (%): 22%. (C) Hemorrhage volume: 102ml, lesion volume: 423ml,
hemorrhage (%): 24%. (D) Hemorrhage volume: 51ml, lesion volume: 347ml, hemorrhage (%): 15%. (E) Hemorrhage volume: 5ml, lesion volume: 411ml,
hemorrhage (%): 1%. (F) Hemorrhage volume: 13ml, lesion volume: 215ml, hemorrhage (%): 6%. (G) Hemorrhage volume: 12ml, lesion volume: 191ml, hemorrhage
(%): 6%.
sample size of our study. Moreover, they only included patients
with PH. In our study, we have shown that patients with large
PH2 are more likely to have poor functional outcomes. This effect
was not seen in the smaller HT subtypes (HI1, HI2, and PH1).
This suggests that hemorrhage volume has only prognostic value
in patients with a PH2.
Assessing the “true” effect of hemorrhage on outcome
warrants adjustment for final infarct size due to their association.
However, the definition of follow-up lesion volume as used
in major studies (a combination of final infarct volume,
swelling, edema, and hemorrhage) causes some difficulty
(16). In patients with HI, adjustment for follow-up lesion
volume will likely result in an accurate estimate of outcome.
Quantifying these hemorrhages can be complicated, as the
delineation of the hemorrhage is not clear. The brain tissue
can be swollen and have petechial bleedings. Delineating the
petechial bleedings results in small hemorrhage volumes, and
the impact of the swollen brain tissue is not taken into
account in this assessment. The lack of including a measure
for swelling can result in a stronger observed association of
the HI1, HI2, and PH1 classifications with the functional
outcome than hemorrhage volume alone. However, large
lesion volumes (incorporating both infarct and parenchymal
swelling) are associated with HT and with a poor functional
outcome, prompting us to include follow-up lesion volume
in the analysis (17). As this measure includes hemorrhage,
infarcted tissue, and edema while the proportion of hemorrhage
is small, it will be correct to adjust for lesion volume.
Conversely, for patients with a PH, hemorrhages can be
large and tend to mask the infarct volume completely. In
these cases, the value of the lesion volume is similar to the
hemorrhage volume. Adding both values to the analysis will
underestimate the association of large hemorrhage volumes with
functional outcome.
Not all patients with sICH have a PH2 with a hematoma
that consists of more than 30% of the infarct volume. When the
infarct is very large, even a hemorrhage of 100ml is <30% of
the infarct volume, but it might cause symptoms and neurologic
deterioration. However, some of the patients classified with sICH
were unlikely to have symptoms due to hemorrhage. In almost
all examples of sICH we showed, a midline shift was present. In
four cases, the hemorrhagemight have contributed to themidline
shift leading to poor functional outcomes. In the other three
cases, the midline shift was probably caused by infarct growth
and not due to hemorrhage. For the classification of sICH, it
is important to determine if it is likely that the hemorrhage is
causing the symptoms as has been proposed in the Heidelberg
Bleeding Classification (5).
An advantage of quantifying hemorrhage volume is that
it might be less sensitive to interobserver variability than
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classifying HT. Quantifying hemorrhage volume can be time-
consuming. However, it may be possible to automatically
quantify hemorrhage volume, as this is accomplished with
subarachnoid hemorrhage and hemorrhagic stroke (18, 19).
In some HT cases, it is difficult to distinguish petechial
hemorrhage from remaining intact cortex throughout the infarct,
also introducing a subjective element when performing a
manual assessment. Making it more accessible and less sensitive
to interobserver variability when classifying HT, it could be
classified as HT or no HT and measure hemorrhage volume only
when a PH is present.
This study had several limitations; some patients had diffuse
brain swelling with hemorrhage, which is complicated to
delineate and could have resulted in smaller hemorrhage volumes
for those patients. Hemorrhage volumes were quantified by one
observer, and therefore, the interobserver variability could not
be assessed. However, measuring hemorrhage volume by one
observer leads to less variation to assess its association with
functional outcome, and eventually, hemorrhage volume might
be assessed by an automated measurement.
In conclusion, hemorrhage volume is associated with
functional outcomes but not independent of total lesion volume.
However, hemorrhage volume could be useful for classifying HT
particularly to measure the extent of a PH.
DATA AVAILABILITY STATEMENT
The datasets presented in this article are not readily available
because of their sensitive nature. Requests to access the
datasets should be directed to the MR CLEAN executive
committee (mrclean-trial.org).
ETHICS STATEMENT
The studies involving human participants were reviewed and
approved by a central medical ethics committee and the research
boards of all participating centers accepted the MR CLEAN
trial. The patients/participants provided their written informed
consent to participate in this study.
AUTHOR CONTRIBUTIONS
WZ, AL, RO, DD, YR, and CM designed the MR CLEAN trial.
OB collected and prepared the data for the trial. KK, OB, AB,
and KT prepared data for this study. KK performed the statistical
analysis, interpreted the results, and drafted the paper. HM, KT,
and CM assisted with the statistical analysis, interpretation of the
results, and drafting the paper. OB, HL, WZ, AL, RO, DD, YR,
and CM critically revised the paper. All authors contributed to
the article and approved the submitted version.
FUNDING
The MR CLEAN trial (Multicenter Randomized Clinical
Trial of Endovascular Treatment for Acute Ischemic Stroke
in the Netherlands) was partly funded by the Dutch Heart
Foundation grant number 2008T30 and by unrestricted
grants from AngioCare BV, Medtronic/Covidien/EV3,
MEDAC Gmbh/LAMEPRO, Penumbra, Inc, Stryker, and
Top Medical/Concentric.
MR CLEAN INVESTIGATORS
Olvert A. Berkhemer, Amsterdam UMC, location AMC, the
Netherlands and Erasmus MC-University Medical Center
Rotterdam, the Netherlands. Puck S.S. Fransen, Erasmus MC-
University Medical Center Rotterdam, the Netherlands. Debbie
Beumer, Erasmus MC-University Medical Center Rotterdam,
the Netherlands and Maastricht University Medical Center
and Cardiovascular Research Institute Maastricht (CARIM),
the Netherlands. Berkhemer, Fransen, and Beumer contributed
equally. Lucie A. van den Berg, Amsterdam UMC, location
AMC, the Netherlands. Hester F. Lingsma, Erasmus MC-
University Medical Center Rotterdam, the Netherlands. Albert
J. Yoo, Massachusetts General Hospital, Boston, United States
of America. Wouter J. Schonewille, Saint Antonius Hospital,
Nieuwegein, the Netherlands. Jan Albert Vos, MD, Sint Antonius
Hospital, Nieuwegein, the Netherlands. Paul J. Nederkoorn,
Amsterdam UMC, location AMC, the Netherlands. Marieke J.H.
Wermer and Marianne A.A. van Walderveen, Leiden University
Medical Center, the Netherlands. Julie Staals, Maastricht
University Medical Center and Cardiovascular Research Institute
Maastricht (CARIM), the Netherlands. Jeannette Hofmeijer
and Jacques A. van Oostayen, Rijnstate Hospital, Arnhem, the
Netherlands. Geert J. Lycklama à Nijeholt and Jelis Boiten, MC
Haaglanden, the Hague, the Netherlands. Patrick A. Brouwer
and Bart J. Emmer, Erasmus MC-University Medical Center
Rotterdam, the Netherlands. Sebastiaan F. de Bruijn and Lukas
C. van Dijk, HAGA Hospital, the Hague, the Netherlands.
L. Jaap Kappelle, University Medical Center Utrecht, the
Netherlands. Rob H. Lo, University Medical Center Utrecht, the
Netherlands. Ewoud J. van Dijk and Joost de Vries, Radboud
University Medical Center, Nijmegen, the Netherlands. Paul
L.M. de Kort and Willem Jan J. van Rooij, Sint Elisabeth
Hospital, Tilburg, the Netherlands. Jan S.P. van den Berg
and Boudewijn A.A.M. van Hasselt, Isala Klinieken, Zwolle,
the Netherlands. Leo A.M. Aerden and René J. Dallinga,
Reinier de Graaf Gasthuis, Delft, the Netherlands. Marieke C.
Visser and Joseph C.J. Bot, Amsterdam UMC, location VU,
Amsterdam, the Netherlands. Patrick C. Vroomen and Omid
Eshghi, University Medical Center Groningen, the Netherlands.
Tobien H.C.M.L. Schreuder and Roel J.J. Heijboer, Atrium
Medical Center, Heerlen, the Netherlands. Koos Keizer and
Alexander V. Tielbeek, Catharina Hospital, Eindhoven, the
Netherlands. HeleenM. den Hertog and Dick G. Gerrits, Medical
SpectrumTwente, Enschede, theNetherlands. RenskeM. van den
Berg-Vos and Giorgos B. Karas, Sint Lucas Andreas Hospital,
Amsterdam, the Netherlands. Ewout W. Steyerberg, Erasmus
MC-University Medical Center Rotterdam, the Netherlands.
H. Zwenneke Flach, Isala Klinieken, Zwolle, the Netherlands.
Henk A. Marquering and Marieke E.S. Sprengers, Amsterdam
UMC, location AMC, the Netherlands. Sjoerd F.M. Jenniskens,
Frontiers in Neurology | www.frontiersin.org 7 November 2020 | Volume 11 | Article 582767
van Kranendonk et al. Hemorrhage Volume Quantification
Radboud University Medical Center, Nijmegen, the Netherlands.
Ludo F.M. Beenen and René van den Berg, Amsterdam UMC,
location AMC, the Netherlands. Peter J. Koudstaal and Wim H.
van Zwam, Erasmus MC-University Medical Center Rotterdam,
the Netherlands. Yvo B.W.E.M. Roos, AmsterdamUMC, location
AMC, the Netherlands. Aad van der Lugt, Erasmus MC-
University Medical Center Rotterdam, the Netherlands. Robert
J. van Oostenbrugge, Maastricht University Medical Center
and Cardiovascular Research Institute Maastricht (CARIM), the
Netherlands. Charles B.L.M. Majoie, Amsterdam UMC, location
AMC, the Netherlands. Diederik W.J. Dippel, Erasmus MC-
University Medical Center Rotterdam, the Netherlands. van
Zwam, Roos, van der Lugt, van Oostenbrugge, Majoie and Dippel
contributed equally.
REFERENCES
1. Hornig CR, Dorndorf W, Agnoli LA. Hemorrhagic cerebral infarction- a
prospective study. Stroke. (1986) 17:179–85. doi: 10.1161/01.STR.17.2.179
2. Group TMAST—ES. Thrombolytic therapy with streptokinase
in acute ischemic stroke. N Engl J Med. (1996) 335:145–
50. doi: 10.1056/NEJM199607183350301
3. Kranendonk KR van, Treurniet KM, Boers AMM, Berkhemer OA, van
den Berg LA, Chales V, et al. Hemorrhagic transformation is associated
with poor functional outcome in patients with acute ischemic stroke
due to a large vessel occlusion. J Neurointerv Surg. (2019) 11:464–
8. doi: 10.1136/neurintsurg-2018-014141
4. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, et al.
Randomised double-blind placebo-controlled trial of thrombolytic therapy
with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet.
(1998) 352:1245–51. doi: 10.1016/S0140-6736(98)08020-9
5. von Kummer R, Broderick JP, Campbell BCV, Demchuk A, Goyal M, Hill
MD, et al. The heidelberg bleeding classification. Stroke. (2015) 46:2981–
6. doi: 10.1161/STROKEAHA.115.010049
6. Fahed R, Ben Maacha M, Ducroux C, Khoury N, Blanc R,
Piotin M, et al. Agreement between core laboratory and study
investigators for imaging scores in a thrombectomy trial. J
Neurointerv Surg. (2018) 10:e30. doi: 10.1136/neurintsurg-2018-0
13867
7. Guenego A, Lecler A, Raymond J, Sabben C, Khoury N, Premal K,
et al. Hemorrhagic transformation after stroke: inter- and intrarater
agreement. Eur J Neurol. (2019) 26:476–82. doi: 10.1111/ene.
13859
8. Berkhemer OA, Fransen PSS, Beumer D, van den Berg LA, Lingsma HF,
Yoo AJ, et al. A randomized trial of intraarterial treatment for acute
ischemic stroke. N Engl J Med. (2015) 372:11–20. doi: 10.1056/NEJMoa14
11587
9. Fransen PSS, Beumer D, Berkhemer OA, van den Berg LA, Lingsma
H, van der Lugt A, et al. MR CLEAN, a multicenter randomized
clinical trial of endovascular treatment for acute ischemic stroke in the
Netherlands: study protocol for a randomized controlled trial. Trials. (2014)
15:343. doi: 10.1186/1745-6215-15-343
10. Boers AM, Marquering HA, Jochem JJ, Besseling NJ, Berkhemer OA, van der
Lugt A, et al. Automated cerebral infarct volume measurement in follow-
up noncontrast CT scans of patients with acute ischemic stroke. AJNR Am
J Neuroradiol. (2013) 34:1522–27. doi: 10.3174/ajnr.A3463
11. Harrell FE. RMS: Regression Modeling Strategies. R package version 6.0-
0. (2017). Available online at: https://CRAN.R-project.org/package=rms
(accessed 13 Jul 2020).
12. Wickham H. ggplot2: Elegant Graphics for Data Analysis. New York, NY:
Springer-Verlag (2009). doi: 10.1007/978-0-387-98141-3
13. Yoshida K, Bohn J. Tableone: Create “Table 1” to Describe Baseline
Charachteristics. R package version 0.11.1. (2015). Available online at: https://
CRAN.R-project.org/package=tableone (accessed July 13, 2020).
14. Christoforidis GA, Slivka A, Mohammad Y, Karakasis C,
Avutu B, Yang M. Size matters. Stroke. (2007) 38:1799–
804. doi: 10.1161/STROKEAHA.106.472282
15. Tao H, Ramadas G, Carrozzella J, Khatri P, Broderick J, Spilker J,
et al. Parenchymal hematoma and total lesion volume in combined
IV/IA revascularization stroke therapy. J Neurointerv Surg. (2012) 4:256–
60. doi: 10.1136/neurintsurg-2011-010062
16. Boers AMM, Jansen IGH, Beenen LFM, Devlin TG, Roman LS, Heo JH, et al.
Association of follow-up infarct volume with functional outcome in acute
ischemic stroke: a pooled analysis of seven randomized trials. J Neurointerv
Surg. (2018) 10:1137–42. doi: 10.1136/neurintsurg-2017-013724
17. Berger C, Fiorelli M, Steiner T, Schäbitz WR, Bozzao L, Bluhmki E, et al.
Hemorrhagic transformation of ischemic brain tissue : asymptomatic or
symptomatic? Stroke. (2001) 32:1330–5. doi: 10.1161/01.STR.32.6.1330
18. Boers AM, Zijlstra IA, Gathier CS, van den Berg R, Slump CH,
Marquering HA, et al. Automatic quantification of subarachnoid
hemorrhage on noncontrast CT. Am J Neuroradiol. (2014)
35:2279–86. doi: 10.3174/ajnr.A4042
19. Xue W, Vegunta S, Zwart CM, Aguilar MI, Patel AC, Hoxworth JM,
et al. Retrospective validation of a computer-assisted quantification model
of intracerebral hemorrhage volume on accuracy, precision, acquisition time
compared with standard ABC/2 manual volume calculation. AJNR Am J
Neuroradiol. (2017) 38:1536–42. doi: 10.3174/ajnr.A5256
Conflict of Interest: Academic medical center Amsterdam received funds from
Stryker for consultations by CM, YR, and OB. CM received research grants
from Cardiovasculair Onderzoek Nederland (CVON)/Dutch Heart Foundation,
European Commission, Twin Foundation and Stryker (all paid to institution).
HM, AB, CM, and YR are shareholders of Nico.lab, a company that focuses on
the use of artificial intelligence for medical image analysis. Erasmus University
Medical Center received funds from Bracco Imaging for consultations by DD.
Erasmus University Medical Center received funds from CVON/Dutch Heart
Foundation, European Commission, Stryker, Penumbra, and Medtronic for the
execution of stroke trials by DD and AL. Maastricht University Medical Center
received funds from Stryker and Cerenovus for consultations by WZ.
The remaining authors declare that the research was conducted in the absence of
any commercial or financial relationships that could be construed as a potential
conflict of interest.
Copyright © 2020 van Kranendonk, Treurniet, Boers, Berkhemer, Coutinho,
Lingsma, van Zwam, van der Lugt, van Oostenbrugge, Dippel, Roos,
Marquering, Majoie and the MR CLEAN investigators. This is an open-access
article distributed under the terms of the Creative Commons Attribution License
(CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) and the copyright owner(s) are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply
with these terms.
Frontiers in Neurology | www.frontiersin.org 8 November 2020 | Volume 11 | Article 582767
